Abstract:The study sought to assess the detrimental effects of isoproterenol (ISO) on major organs and investigate the potential reversibility of these adverse reactions in mice. Male mice were divided into normal control, 0.2 mg/kg.d and 3.0 mg/kg.d ISO groups, and were subcutaneously administered of the respective doses for 14 consecutive days. Subsequently, a recovery period experiment was conducted, replicating the aforementioned procedure, followed by an additional 2-week recovery period for the mice. Following 14 consecutive days of administration, mice treated with ISO exhibited notable cardiac damage manifested by abnormal ECG patterns, dysregulated energy metabolism, elevated cardiac hypertrophy, and increased heart pathological score. Additionally, the administration of ISO resulted in liver and kidney damage, as evidenced by increased pathological score, serum albumin level, and urea level. Lung damage was also observed, indicated by an increase in lung pathological score. Furthermore, the administration of ISO at a dosage of 3.0 mg/kg.d resulted in a decrease in liver mass index, serum iron content, and an increase in lung mass index. After a 2-week recovery period, mice treated with ISO showed abnormalities in ECG patterns and dysregulated myocardial energy metabolism, accompanied by a decrease in serum iron content. Histopathological examinations revealed continued pathological changes in the heart and lung, as well as significant hemosiderin deposition in the spleen. Furthermore, the group treated with ISO at a dosage of 3.0 mg/kg.d showed an increase in serum AST and TP levels. In summary, the study demonstrates that both 0.2 mg/kg.d and 3.0 mg/kg.d doses of ISO can induce damage to the heart, liver, lung, kidney, and spleen, with the higher dose causing more severe injuries. After a 2-week withdrawal period, the liver, kidney, and thymus injuries caused by 0.2 mg/kg ISO shows signs of recovery, while damage to the heart, lung, and spleen persists. The thymus injury mostly recovers, with minimal kidney pathology, but significant damage to the heart, liver, and lung remains even after the withdrawal period for the 3.0 mg/kg ISO dose.

Treatment Withβ-Adrenoceptor Agonist Isoproterenol Reduces Non- Parenchymal Cell Responses in LPS/D-Galn-induced Liver Injury

Treatment with β-Adrenoceptor Agonist Isoproterenol Reduces Non-parenchymal Cell Responses in LPS/D-GalN-Induced Liver Injury

The Inhibition of Bruton Tyrosine Kinase Alleviates Acute Liver Failure via Downregulation of NLRP3 Inflammasome.

Isoliquiritigenin Alleviates LPS/ D-GalN-induced Acute Liver Failure by Activating the PGC-1α/ Nrf2 Pathway to Reduce Oxidative Stress and Inflammatory Response.

Endotoxin tolerance ameliorates lipopolysaccharide/D-galactosamine-induced acute liver failure by negative regulation of the NF-κB/NLRP3 and activation of Nrf2/HO-1 via Sitr1

Activation of Liver X Receptors Attenuates Endotoxin-Induced Liver Injury in Mice with Nonalcoholic Fatty Liver Disease

[Effects of Isorhapontigenin on Lipopolysaccharide-Induced Acute Lung Injury in Mice]

Myeloid-derived TLR4-TRIF signaling pathway mediates oxidative stress in LPS/D-GalN-induced acute liver failure

Protective Role of 4-Octyl Itaconate in Murine LPS/D-GalN-Induced Acute Liver Failure via Inhibiting Inflammation, Oxidative Stress, and Apoptosis

Protective Effect of SKLB010 Against D-Galactosamine/lipopolysaccharide-induced Acute Liver Failure Via Nuclear Factor-Κb Signaling Pathway in Macrophages

Multiple organs injury and myocardial energy metabolism disorders induced by isoproterenol

Isoflurane Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting ROS-mediated NLRP3 Inflammasome Activation.

Selective PPARδ Agonist GW501516 Protects Against LPS-Induced Macrophage Inflammation and Acute Liver Failure in Mice via Suppressing Inflammatory Mediators

Inhibitions of NF-κB and TNF-α Result in Differential Effects in Rats with Acute on Chronic Liver Failure Induced by d -Gal and LPS

Isoorientin protects lipopolysaccharide-induced acute lung injury in mice via modulating Keap1/Nrf2-HO-1 and NLRP3 inflammasome pathways

Glucocorticoids Alleviates Lipopolysaccharide-Induced Acute Liver Injury Associated With Promoting The Expression Of Ntcp And Bsep

Early Use of Dexamethasone Increases Nr4a1 in Kupffer Cells Ameliorating Acute Liver Failure in Mice in a Glucocorticoid Receptor-Dependent Manner

Chronic Isoproterenol Stimulation Induces Cardiomyocyte Apoptosis Through P38-Cytokine-inos Pathway

α-Galactosylceramide and its analog OCH differentially affect the pathogenesis of ISO-induced cardiac injury in mice

Inhibition Of Glycogen Synthase Kinase 3 Beta Ameliorates D-Galn/Lps-Induced Liver Injury By Reducing Endoplasmic Reticulum Stress-Triggered Apoptosis

Antioxidation, anti-inflammation and anti-apoptosis by paeonol in LPS/d-GalN-induced acute liver failure in mice.